# EVID AI

Extract the up-to-date evidence you need from the global medical literature

- ✓ FASTER
- ✓ MORE EFFICIENTLY
- ✓ FROM A GREATER BREADTH OF SOURCES

Click on image to watch introductory video.

- Are there situations in which you can't find answers to your urgent scientific questions in the time available?

- Do the results of your literature search still require the manual reviewing of, and data extraction from, vast quantities of papers?

- Can you be sure the answers you get from Google or any other search facility are relevant and up to date?

EVID AI provides the solution

15% MORE ARTICLES
AND 15x FEWER
IRREVELENT ONES

59x FASTER
THAN SEARCHES
USING PUBMED

**HIGH QUALITY**
RESULTS DEMONSTRATED
IN PUBLISHED LITERATURE

EVID AI is a unique AI-powered platform that provides the world's largest, up-to-date database of healthcare literature results, searching over 100 million data points to help you find the evidence you need.

Whether your query is part of a systematic literature review or an ad hoc question addressing a business-critical situation, EVID AI can power your search including PubMed, the latest conference papers, and any custom articles you wish to add, before offering a range of filtering options based on that specific criterion and a shortlist of results.

**1.** EVID AI supports both simple and Boolean searches using the same modifiers as PubMed.

2. The AI creates filtering options specific to the search undertaken.

3. The user is presented with carefully curated results.

However, EVID AI is far more than just an AI-curated database of results. Programmed through exposure to tens of thousands of training data points, the AI employs machine reading and semantic understanding to locate data within an abstract, categorize the language around it, extract it, and then reproduce it in structured evidence tables.

4. Machine learning is applied to extract data from the text and place it into structured evidence tables.

① Unstructured text (sentences) processed by our AI

Results: Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]). Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%). Furthermore, guselkumab significantly improved patient-reported outcomes through week 48. Adverse event rates were comparable between treatments.

What do these values refer to?

② The AI assesses up to 25 million articles an hour, structuring the data

INTERVENTION	OUTCOME	MEASUREMENT
GUSELKUMAB	INVESTIGATOR GLOBAL ASSESSMENT 0/1 AT WEEK 48	80.5%
ADALIMUMAB	INVESTIGATOR GLOBAL ASSESSMENT 0/1 AT WEEK 48	55.4%

5. Often in only a matter of minutes, EVID AI will produce transparent, reproducible, and exportable results. The tables immediately provide the user with the data they need without the need to review individual abstracts.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial (2017)

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB

Journal of the American Academy of Dermatology, 3, 405-417.

`Source: PubMed` `Subject: Human` `Trial` `Intervention` `Prospective` `Drug Therapy` `phase 3` `double blind`

`Manage paper data`

Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and Psoriasis Area and Severity Index 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%).

Result	Intervention/Group	Outcome
284 of 334	Guselkumab	for Investigator Global Assessment 0/1, at week 16
220 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	for Investigator Global Assessment 0/1, at week 16
245 of 334	Guselkumab	Psoriasis Area and Severity Index 90, at week 16
166 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	Psoriasis Area and Severity Index 90, at week 16
281 of 334	Guselkumab	for Investigator Global Assessment 0/1 at, week 24
206 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	for Investigator Global Assessment 0/1, week 24
268 of 334	Guselkumab	Psoriasis Area and Severity Index 90 at, week 24

Could EVID AI revolutionize **your** work?

EVID AI does not replace human expertise. The experts still frame the question and interpret the results, but the AI does the heavy lifting for data gathering, leaving the scientist free to focus their time and expertise on evaluating and communicating the evidence they find.

Already used by some of the world's leading pharmaceutical companies, contact us to find out what EVID AI can do for you and your team.

" EVID's ability to review conference data and allow us to filter on study types and outcomes saved us weeks of manual effort, especially important for this urgent update. "
Pharma Client

BOOK A PRIVATE DEMO
solutions@genesisrg.com

WATCH A PRESENTATION

REVIEW THE LITERATURE

Matt Michelson,
President, GENESIS AI

ASK A QUESTION
questions@genesisrg.com

If you haven't already, you can view our two-minute animated EVID AI explainer video here >>   **WATCH VIDEO**

About Genesis Research

Genesis Research is an international Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) research organization that supports the life sciences industry. A leader in evidence strategy, generation, and communication, the company offers tech-enabled, dedicated partnerships delivered via a unique engagement model that enables pharmaceutical, and biotech companies to address complex needs with unmatched timeliness, and quality.

Innovators in RWE-based solutions and entirely data agnostic, Genesis Research is also an established leader in the development of advanced technological solutions such as dashboards, data portals, and EVID AI, the world's largest, up-to-date database of healthcare literature results.

Visit www.genesisrg.com or email solutions@genesisrg.com.